File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity

TitleGut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity
Authors
KeywordsBNT162b2 (Pfizer-BioNTech)
COVID-19 vaccine
gut microbiota
vaccine
vaccine immunogenicity
Issue Date27-Feb-2025
PublisherFrontiers Media
Citation
Frontiers in Immunology, 2025, v. 16 How to Cite?
Abstract

Introduction: BNT162b2 immunogenicity wanes with time and we investigated association between gut microbiota and longer-term immunogenicity.

Methods: This cohort study prospectively recruited adult BNT162b2 two-dose recipients from three vaccination centers in Hong Kong. Blood samples were collected at baseline and day 180 after first dose, and tested for neutralizing antibodies (NAb) against receptor-binding domain (RBD) of wild type SARS-CoV-2 virus using chemiluminescence immunoassay. Shotgun DNA metagenomic sequencing was performed to characterize baseline stool microbiome. Baseline metabolites were measured by gas and liquid chromatography-tandem mass spectrometry (GC-MS/MS and LC-MS/MS). Primary outcome was persistent high NAb response (defined as top 25% of NAb level) at day 180. Putative bacterial species and metabolic pathways were identified using linear discriminant analysis [LDA] effect size analysis. Multivariable logistic regression adjusting for clinical factors was used to derive adjusted odds ratio (aOR) of outcome with bacterial species and metabolites.

Results: Of 242 subjects (median age: 50.2 years [IQR:42.5-55.6]; male:85 [35.1%]), 61 (25.2%) were high-responders while 33 (13.6%) were extreme-high responders (defined as NAb≥200AU/mL). None had COVID-19 at end of study. Ruminococcus bicirculans (log10LDA score=3.65), Parasutterella excrementihominis (score=2.82) and Streptococcus salivarius (score=2.31) were enriched in high-responders, while Bacteroides thetaiotaomicron was enriched in low-responders (score=-3.70). On multivariable analysis, bacterial species (R. bicirculans–aOR: 1.87, 95% CI: 1.02-3.51; P. excrementihominis–aOR: 2.2, 95% CI: 1.18-4.18; S. salivarius–aOR: 2.09, 95% CI: 1.13-3.94) but not clinical factors associated with high response. R. bicirculans positively correlated with most metabolic pathways enriched in high-responders, including superpathway of L-cysteine biosynthesis (score=2.25) and L-isoleucine biosynthesis I pathway (score=2.16) known to benefit immune system. Baseline serum butyrate (aOR:10.00, 95% CI:1.81-107.2) and isoleucine (aOR:1.17, 95% CI:1.04-1.35) significantly associated with extreme-high vaccine response.

Conclusion: Certain gut bacterial species, metabolic pathways and metabolites associate with longer-term COVID-19 vaccine immunogenicity.


Persistent Identifierhttp://hdl.handle.net/10722/355314

 

DC FieldValueLanguage
dc.contributor.authorNg, Ho Yu-
dc.contributor.authorLiao, Yunshi-
dc.contributor.authorCheung, Ching Lung-
dc.contributor.authorZhang, Ruiqi-
dc.contributor.authorChan, Kwok Hung-
dc.contributor.authorSeto, Wai-Kay-
dc.contributor.authorLeung, Wai K-
dc.contributor.authorHung, Ivan F N-
dc.contributor.authorLam, Tommy TY-
dc.contributor.authorCheung, Ka Shing-
dc.date.accessioned2025-04-03T00:35:07Z-
dc.date.available2025-04-03T00:35:07Z-
dc.date.issued2025-02-27-
dc.identifier.citationFrontiers in Immunology, 2025, v. 16-
dc.identifier.urihttp://hdl.handle.net/10722/355314-
dc.description.abstract<p><strong>Introduction:</strong> BNT162b2 immunogenicity wanes with time and we investigated association between gut microbiota and longer-term immunogenicity.</p><p><strong>Methods:</strong> This cohort study prospectively recruited adult BNT162b2 two-dose recipients from three vaccination centers in Hong Kong. Blood samples were collected at baseline and day 180 after first dose, and tested for neutralizing antibodies (NAb) against receptor-binding domain (RBD) of wild type SARS-CoV-2 virus using chemiluminescence immunoassay. Shotgun DNA metagenomic sequencing was performed to characterize baseline stool microbiome. Baseline metabolites were measured by gas and liquid chromatography-tandem mass spectrometry (GC-MS/MS and LC-MS/MS). Primary outcome was persistent high NAb response (defined as top 25% of NAb level) at day 180. Putative bacterial species and metabolic pathways were identified using linear discriminant analysis [LDA] effect size analysis. Multivariable logistic regression adjusting for clinical factors was used to derive adjusted odds ratio (aOR) of outcome with bacterial species and metabolites.</p><p><strong>Results:</strong> Of 242 subjects (median age: 50.2 years [IQR:42.5-55.6]; male:85 [35.1%]), 61 (25.2%) were high-responders while 33 (13.6%) were extreme-high responders (defined as NAb≥200AU/mL). None had COVID-19 at end of study. <em>Ruminococcus bicirculans</em> (log<sub>10</sub>LDA score=3.65), <em>Parasutterella excrementihominis</em> (score=2.82) and <em>Streptococcus salivarius</em> (score=2.31) were enriched in high-responders, while <em>Bacteroides thetaiotaomicron</em> was enriched in low-responders (score=-3.70). On multivariable analysis, bacterial species (<em>R. bicirculans</em>–aOR: 1.87, 95% CI: 1.02-3.51; <em>P. excrementihominis</em>–aOR: 2.2, 95% CI: 1.18-4.18; S. <em>salivarius</em>–aOR: 2.09, 95% CI: 1.13-3.94) but not clinical factors associated with high response. <em>R. bicirculans</em> positively correlated with most metabolic pathways enriched in high-responders, including superpathway of L-cysteine biosynthesis (score=2.25) and L-isoleucine biosynthesis I pathway (score=2.16) known to benefit immune system. Baseline serum butyrate (aOR:10.00, 95% CI:1.81-107.2) and isoleucine (aOR:1.17, 95% CI:1.04-1.35) significantly associated with extreme-high vaccine response.</p><p><strong>Conclusion:</strong> Certain gut bacterial species, metabolic pathways and metabolites associate with longer-term COVID-19 vaccine immunogenicity.</p>-
dc.languageeng-
dc.publisherFrontiers Media-
dc.relation.ispartofFrontiers in Immunology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectBNT162b2 (Pfizer-BioNTech)-
dc.subjectCOVID-19 vaccine-
dc.subjectgut microbiota-
dc.subjectvaccine-
dc.subjectvaccine immunogenicity-
dc.titleGut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity-
dc.typeArticle-
dc.identifier.doi10.3389/fimmu.2025.1534787-
dc.identifier.scopuseid_2-s2.0-105000424326-
dc.identifier.volume16-
dc.identifier.eissn1664-3224-
dc.identifier.issnl1664-3224-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats